Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 70Years
All Genders
Healthy Volunteers
NCT07528495

A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's

Led by All India Institute of Medical Sciences · Updated on 2026-05-06

396

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

Sponsors

A

All India Institute of Medical Sciences

Lead Sponsor

A

All India Institute of Medical Sciences, Rishikesh

Collaborating Sponsor

AI-Summary

What this Trial Is About

The present study is a phase II/III prospective randomized trial designed to determine whether eliminating of post operative radiotherapy to regional lymphatics in pN0-N1oral cavity is associated with similar treatment outcomes.

CONDITIONS

Official Title

A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's

Who Can Participate

Age: 18Years - 70Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18 or above and less than 70 years
  • Histologically confirmed pT1-4 squamous cell carcinoma of the oral cavity
  • Undergoing radical excision and ipsilateral or bilateral neck dissection
  • Presence of high-risk features: positive or close (≤ 5mm) surgical margin, lymphovascular invasion, perineural invasion, or pT3-4 tumor stage
  • At least one dissected hemi-neck with 12 or more lymph nodes recovered
  • Pathological N0 or N1 neck status with high-risk features receiving radiotherapy
  • Brandwein-Gensler histological risk assessment performed
  • Karnofsky performance score of 70 or higher
  • Ability to complete MD Anderson Dysphagia Inventory and EORTC quality of life questionnaires in English or Hindi
  • Postoperative radiotherapy preferably started within 6 weeks of surgery (up to 1-2 weeks delay allowed for wound healing or logistics)
  • Written informed consent for treatment
  • Available for long-term follow-up
Not Eligible

You will not qualify if you...

  • Non-squamous cell carcinoma histology
  • Presence of distant metastases
  • pT1-2 disease without high-risk features
  • Pathological N2 or N3 neck disease
  • Need for re-irradiation due to recurrent disease
  • Inadequate neck dissection (less than 12 lymph nodes examined)
  • Primary tumor reaching within 1 cm of midline with only ipsilateral neck dissection
  • Postoperative radiotherapy initiated later than 8 weeks after surgery
  • Previous radiotherapy to head and neck region
  • Any invasive malignancy within past 2 years except non-melanomatous skin cancer or cervical carcinoma in situ
  • Age under 18 or over 70 years
  • Brandwein-Gensler histological risk assessment not performed

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Nci, Aiims

Jhajjar, Haryana, India, 124105

Actively Recruiting

Loading map...

Research Team

A

Aman Sharma, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here